AstraZeneca Aktie News

UK drugmaker AstraZeneca said on Thursday it would invest $15 billion in China through 2030 to expand medicines manufacturing and research and development, an announcement made during British Prime Minister Keir Starmer's visit to Beijing.

Agreement builds on long-established partnership and demonstrates the strength and importance of industry/academic scientific collaborations Agreement builds on long-established partnership and demonstrates the strength and importance of industry/academic scientific collaborations

Starmer brings nearly 60 business and cultural groups on first U.K. leader visit to China in eight years. Talks with Xi and Li focus on trade, investment and national security.

Analysts at Citi see AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) as 'the top pick' among European pharmaceutical firms. and rate the FTSE 100 stock as a 'buy'.

UK-headquartered pharmaceutical firm AstraZeneca's AZN.L) CEO Pascal Soriot will join Prime Minister Keir Starmer's trip to China this week, said a source familiar with the matter, as Britain seeks to strengthen engagement with Beijing at a time of strained relations with Washington.

AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New York Stock Exchange, effective after market close on January 30, 2026.

The next earnings season for European pharmaceuticals is shaping up as a test of discipline rather than momentum, with UK stocks firmly in the spotlight. That is the message from Deutsche Bank, which says the sector's strong start to the year has already pulled forward some optimism.

Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools and automated labs to unlock efficiency gains across their pipeline.